PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Biostatistics, GlaxoSmithKline Research and Development, Brentford, Middlesex, UK. Electronic address: oliverkeene405@gmail.com.\', \'Data Science & Artificial Intelligence, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.\', \'Biostatistics, ICON Clinical Research UK Ltd, Marlow, Buckinghamshire, UK.\', \'Clinical Development and Analytics, Novartis Pharma AG, Basel, Switzerland.\']
?:citedBy
  • -1
?:creator
?:doi
  • S1551-7144(21)00230-510.1016/j.cct.2021.106494
?:doi
?:hasPublicationType
?:journal
  • Contemporary clinical trials
is ?:pmid of
?:pmid
?:pmid
  • 34186242
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.536
?:rankingScore_hIndex
  • 48
is ?:relation_isRelatedTo_publication of
?:title
  • Why ITT analysis is not always the answer for estimating treatment effects in clinical trials.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34186242>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34186242>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all